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Results: Preclinical and MCI carriers showed higher YKL-40 levels. There was a significant inter-
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Sporadic Alzheimer’s disease (AD) is understood as a
clinico-biological continuum ranging from normal cognition
to dementia [1,2]. The two major neuropathologic hallmarks
of Alzheimer’s disease are extracellular fibrillary amyloid-b
(Ab) plaques and intracellular neurofibrillary tau tangles.
Amyloid and tau pathology can be monitored in vivo
quantifying these proteins in cerebrospinal fluid (CSF) andimer’s Association. This is an open access article under the CC BY-NC-ND
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stages of AD, this new conceptualization recognizes the
presence of an asymptomatic phase, referred to as the
preclinical stage of AD, in which cognition is within
normal ranges but abnormal amyloid markers are already
present [3].
The apolipoprotein E (APOE) is the strongest genetic risk
factor for AD. The APOE gene has three major alleles (ε2,
ε3, and ε4) which code for different isoforms of the ApoE.
ApoE regulates the metabolism of lipids by directing their
transport, delivery, and distribution through ApoE receptors
and associated proteins [4]. Carriers of at least one ε4 allele
(APOE ε4) are 3–4 times more likely to develop AD than
noncarriers [5] and show significant atrophy especially in re-
gions susceptible to AD-related atrophy such as the hippo-
campus [6–8]. In the central nervous system, the ApoE
protein is synthesized and secreted mainly by astrocytes
[9], and to a lesser extent by microglia [10]. Microglia and
astrocytes are the two major types of glial cells involved in
the regulation of the immune response to pathological pro-
cesses in the brain. Several neuropathological, epidemiolog-
ical, and genetic studies have shown evidence for the
involvement of the innate-immunity in early stages of the
pathological cascade leading to Alzheimer’s dementia
[11,12]. In addition to its role for lipid metabolism, APOE
has an important role in Ab aggregation and degradation
[4,13] which may be mediated by glial cells: the ApoE has
been described to promote the localization and degradation
of Ab deposits by astrocytes [14] and bind to apoptotic neu-
rons to promote phagocytosis by the microglia [15].
Recently, CSF concentrations of YKL-40 and sTREM2
have been linked to the cerebral regulation of astroglial
and microglial activation along the AD continuum, respec-
tively. YKL-40 (CHI3L1, HC gp-39) is a homolog to chito-
triosidase but lacks chitinolytic activity [16]. YKL-40
secreted into the CSF is mostly produced in reactive astro-
cytes and has been shown to be increased in Alzheimer’s
disease and in healthy subjects during late middle age
[17–19]. Previous cross-sectional analyses have not detected
differences in CSF YKL-40 levels between APOE ε4 car-
riers and noncarriers [18–21]. However, a longitudinal
study reported a steeper increase of CSF YKL-40 levels
with aging in cognitively healthy middle-aged APOE ε4 car-
riers relative to noncarriers [19].
The triggering receptor expressed on myeloid cells 2
(TREM2) is an innate immune receptor expressed on the sur-
face of microglia which is involved in regulating phagocy-
tosis, removal of apoptotic neurons and inhibition of
proinflammatory response [22–25]. Homozygous loss-of-
function mutations in the TREM2 gene cause Nasu-Hakola
disease, a rare and fatal neurodegenerative disorder, and
fronto-temporal dementia (FTD)-like syndrome [26]. Hetero-
zygous missense mutations have been recently described to
significantly increase the risk of Alzheimer’s disease, as
well as other neurodegenerative diseases, with an odds ratio
similar to that of carrying an APOE ε4 allele [27,28]. Inaddition, heterozygous TREM2 mutation carriers display
increased density of amyloid plaques and neurofibrillary
tangles, to present with upregulated proinflammatory
cytokines and with downregulated protective markers [29].
The TREM2 receptor undergoes proteolytic processing,
releasing its ectodomain into the extracellular space as a sol-
uble variant (sTREM2) via shedding by a disintegrin andmet-
alloproteinase (ADAM) proteases and can be detected in
human plasma and CSF [30,31]. CSF sTREM2 levels are
increased in the early symptomatic stages of AD [32–34].
The TREM2 receptor has been reported to bind ApoE
[15,35]. In addition, TREM2 expression is differentially
modulated by APOE, the ε4 allele causing a
proinflammatory environment in brain [36]. However, CSF
sTREM2 levels do not seem to differ between APOE ε4 car-
riers and noncarriers [32,33].
The association between CSF biomarkers and regional
cerebral structural changes contributes to understanding
the AD pathological mechanisms. Regarding CSF glial
markers in early AD patients, our group has reported positive
associations between gray-matter volume versus CSF YKL-
40 and sTREM2—independently—in temporal areas, after
accounting for p-tau associated atrophy [37,38]. In a
sample of cognitively normal controls and patients with
amnestic mild cognitive impairment (MCI), a negative
correlation between CSF YKL-40 and cortical thickness in
temporal areas was found in subjects with abnormal CSF
Ab levels but not in the amyloid-negative participants
[20]. These results illustrate the dynamic nature of the struc-
tural correlates of glial CSF biomarkers across the contin-
uum of AD [12].
The aim of this work is to study whether the APOE geno-
type has an impact on the glial response along the clinico-
biological continuum of AD. To this end, we measured the
CSF concentrations of two biomarkers associated to astro-
glial and microglial activation (YKL-40 and sTREM2,
respectively) and determined the presence of at least one
ε4 allele of the APOE gene in four groups of subjects:
healthy controls, a group of preclinical AD subjects, MCI
patients due to AD, and a group of patients with mild demen-
tia due to Alzheimer’s disease. We then sought for differ-
ences between APOE ε4 carriers and noncarriers in the
levels of the glial CSF biomarkers, as well as in their respec-
tive cerebral volumetric correlates.2. Materials and methods
2.1. Participants
A sample of 110 participants was recruited at the AD and
other cognitive disorders unit, from the Hospital Clinic i Uni-
versitari (Barcelona). The study was approved by the local
institutional review board (Comite Etic de Recerca Clınica
de l’Hospital Clınic de Barcelona), and all participants gave
written informed consent to participate. Subjects underwent
clinical and neuropsychological assessment, lumbar puncture,
Table 1
Demographic characteristics of the study participants (mean 6 standard deviation)
Variables
Ctrl Pre-AD MCI AD
Noncarriers (ε42) Carriers (ε41) Noncarriers (ε42) Carriers (ε41) Noncarriers (ε42) Carriers (ε41) Noncarriers (ε42) Carriers (ε41)
N 44 5 11 8 13 14 8 7*
Age (years) 62.18 6 6.76 59.60 6 7.92 68.09 6 8.42 68.38 6 8.03 70.23 6 8.72 70.36 6 6.16 65.88 6 9.92 68.57 6 10.72y
Gender; females, n (%) 28 (63.64) 4 (80.00) 8 (72.73) 6 (75.00) 8 (61.54) 7 (50.00) 7 (87.50) 4 (57.14)*
Ab42 (mg/mL) 774.67 6 186.86 670.71 6 99.86 383.66 6 105.34 347.01 6 52.25 330.52 6 87.10 367.24 6 73.22 306.17 6 60.96 302.67 6 97.87
z
t-tau (mg/mL) 219.55 6 69.53 225.43 6 54.42 251.40 6 161.19 370.58 6 133.72 691.20 6 562.45 820.83 6 258.59 779.85 6 494.00 945.95 6 510.99z
p-tau (mg/mL) 50.90 6 12.18 46.44 6 4.36 54.73 6 29.99 67.55 6 19.67 98.67 6 54.97 116.19 6 25.60 105.55 6 47.25 124.32 6 46.64z
YKL_40 (mg/mL) 271.36 6 104.49 252.65 6 32.67 283.74 6 137.05 341.16 6 51.71 364.87 6 123.07 490.16 6 133.03 327.79 6 133.27 339.96 6 107.99z
sTREM2x (a.u.) 0.4257 6 0.2200 0.4042 6 0.2178 0.4793 6 0.4183 0.6050 6 0.3486 0.6772 6 0.3788 0.7400 6 0.4708 0.4359 6 0.1540 0.7588 6 0.4561z
MMSE 28.516 1.49% 29.006 0.71% 27.916 1.64% 26.866 1.95% 25.086 2.23% 24.796 3.29% 23.006 6.14% 22.866 2.91%z
FCSRT-DTR 14.65 6 1.21 14.20 6 1.92 14.18 6 2.27 13.29 6 1.80 7.25 6 5.19 5.31 6 5.44 5.83 6 5.71 3.14 6 3.02z
FCSRT-DFR 10.07 6 2.19 11.20 6 1.48 9.45 6 3.33 7.71 6 2.29 3.58 6 3.78 1.69 6 2.93 2.67 6 3.33 0.57 6 1.13z
Left hippocampusk (cm3) 5.34 6 0.38 5.07 6 0.11 5.12 6 0.76 5.10 6 0.43 5.31 6 0.83 4.83 6 0.36 5.19 6 0.80 5.32 6 0.49
Right hippocampusk (cm3) 5.25 6 0.30 5.02 6 0.18 5.19 6 0.80 5.10 6 0.59 5.22 6 0.77 4.89 6 0.31 5.35 6 0.92 5.31 6 0.79
Abbreviations: Pre-AD, preclinical Alzheimer’s disease;MCI, mild cognitive impairment;MMSE,Mini–Mental State Examination; FCSRT, Free and Cued Selective Reminding Test; DTR, delayed total recall;
DFR, delayed free recall; ANOVA, analysis of variance; CSF, cerebrospinal fluid; TIV, total intracranial volume.
*Chi-square test (P , .05).
yANOVA: diagnostic category (P , .05).
zANOVA: diagnostic category after accounting for age and sex (P , .05).
xCSF sTREM2 relative to an internal standard (a.u.: arbitrary units).
kHippocampal volumes corrected for TIV (see Methods).
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Ab42, tau phosphorylated at position threonine 181 (p-tau),
and total tau protein (t-tau) were determined. Genomic
DNAwas extracted from peripheral blood using the QIAamp
DNA blood minikit (Qiagen AG, Basel, Switzerland). APOE
genotyping was performed by polymerase chain reaction
amplification and HhaI restriction enzyme digestion. Subjects
were categorized as APOE ε4 carriers if they had at least one
ε4 allele or as noncarriers otherwise.
Clinical and neuropsychological examination was per-
formed by specialized neurologists and neuropsychologists.
A clinical committee formed by two neurologists and one
neuropsychologist established the diagnoses. All tests were
administered in Spanish language; normative neuropsycho-
logical data were collected previously from a sample of
healthy elders from Spain [39] and cutoff values were
derived to be 1.5 standard deviations below the mean, after
taking into account age and education. Control subjects
(N 5 48) were cognitively normal, defined according to
Mini–Mental State Examination (MMSE) scores above 24
according to recommended diagnostic cutoffs for the local
population [40], objective cognitive performance within
the normal range in all tests (test battery below), clinical de-
mentia rating (CDR) scale score of 0, no significant psychi-
atric symptoms or previous neurological disease, and a CSF
biomarker profile inconsistent with AD pathology.
Preclinical AD (Pre-AD) subjects (N 5 19) were defined
according to well-established research criteria [3]: MMSE
scores above the local diagnostic threshold value (24), objec-
tive cognitive performance within the normal range in all
tests (test battery below), CDR scale score of 0, no signifi-
cant psychiatric symptoms or previous neurological disease,
and decreased CSF Ab42 below 500 pg/mL. This threshold
value was selected according to recommended reference
values [41] and corresponded with the 10th percentile in a
sample of healthy individuals in that study.
MCI due to AD patients (N5 27) were defined according
to the National Institute on Aging -Alzheimer’s Association
criteria [42]. They had an amnesic MCI clinical picture,
MMSE scores equal to or below 24 or abnormal scores in
the Free andCuedSelectiveRemindingTest (FCSRT) accord-
ing to age and educational level (immediate free recall,15 or
immediate total recall ,30 or delayed free recall ,6 or de-
layed total recall ,11), preserved daily-living activities as
measured by the Functional Activities Questionnaire (FAQ,
score ,6), and CSF Ab42 levels below 500 pg/mL, plus a
marker of neurodegeneration: high t-tau (over 450 pg/mL),
p-tau (over 75 pg/mL) [41], or medial temporal atrophy [43].
Mild dementia due to AD (N5 15) was defined according
to the NIA-AA criteria [42]. Patients had a clinical picture
compatible with probable Alzheimer’s disease and verified
through a neuropsychological examination. They had
abnormal MMSE or FCSRT scores according the previously
described cutoff values, plus impaired daily-living activities
as measured by the FAQ (6) and abnormal CSF biomarkers
as defined for the MCI group.Demographic information, distribution of APOE geno-
types, neuropsychology, and CSF biomarker values are
detailed in Table 1.
2.2. CSF sampling
CSF was collected by lumbar puncture between 9 and 12
AM. Samples were processed within 1 hour, centrifuged at
4C for 10 minutes at 2000! g and stored in polypropylene
tubes at280C. CSFAb42, p-tau, and t-tau levels detection
was performed by enzyme-linked immunosorbent assay
from Innogenetics (Ghent, Belgium). Determination of the
CSF YKL-40 followed the procedure described in [37],
and determination of the CSF sTREM2 was according the
process described in [33].
2.3. Image acquisition and preprocessing
Subjects were examined on a 3TMRI scanner (Magnetom
Trio Tim, Siemens Medical Solutions, Germany) with the
acquisition protocol described in [37]. Themean time interval
between the lumbar puncture and the MRI was 41 days and
ranged between 1 and 134 days. No between-group differ-
ences were found for the time interval between CSF sampling
and MRI scans. MRI data were visually inspected to discard
any image artifacts and anatomical anomalies before submis-
sion to a voxel-based morphometry (VBM) analysis. Briefly,
gray-matter parcellations were normalized, modulated, and
smoothed with 8 mm of full width at half maximum
(FWHM) Gaussian kernel. See [37] for further details. In
addition, hippocampal volumes were automatically calcu-
lated for each subject with an in-house implementation for
SPM8 of the Individual Atlases using Statistical Parametric
Mapping toolbox [44] using the automated anatomical label-
ing atlas [45]. Hippocampal volumes were corrected for total
intracranial volume (TIV), calculated as the sum of gray-
matter, white-matter, and CSF volumes. Corrected values
were calculated as the unstandardized residuals of the regres-
sion between hippocampal values and TIV, plus the mean
value of the uncorrected hippocampal volumes.
2.4. Statistical analysis
The probability distribution of both CSF glial biomarkers
did not meet normality criteria according to the Shapiro-
Wilk normality test (both, P , .001). Therefore, values
were log-transformed (after transformation: YKL-40,
P 5 .227; sTREM2, P 5 .699). In the remainder of the
text, CSF YKL-40 and sTREM2 will refer to the log-
transformed variables. Finally, a regression analysis was per-
formed to assess whether CSF YKL-40 and sTREM2 were
associated between them in the whole sample and broken
down by diagnostic group.
Age-corrected core AD biomarkers were compared be-
tween carriers and noncarriers for each diagnostic group.
For exploring the independent relationship between each
CSF YKL-40 and sTREM2 and relevant factors, two analysis
Fig. 1. Age-corrected levels of CSF YKL-40 (top) and sTREM2 (bottom)
for all diagnostic groups broken down by APOE4 genotype. *P , .1;
**P , .05. Abbreviations: CSF, cerebrospinal fluid; MCI, mild cognitive
impairment; Pre-AD, preclinical Alzheimer’s disease.
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(model 1) included age and sex as covariates and diagnostic
group and APOE ε4 status as categorical factors (diagnostic
model). In the second one (model 2), diagnostic group was
substituted by CSF Ab and p-tau levels (biomarker model).
In both models, the dependent variable was the concentration
of glial CSF biomarkers. Model 1 allowed us to assess the
impact of APOE ε4 genotype on these concentrations by
modeling AD progression with diagnostic categories,
whereas in model 2, disease progression is modeled using
core CSF AD biomarkers as continuous covariates. Initially,
all two-way interactions were included in the model but
were removed if they did not reach a statistical significance
level of P, .1. In addition, two-sample t tests were computed
to compare age-corrected glial biomarker levels between
APOE ε4 carriers and noncarriers for each diagnostic group.
For all tests, statistical significance was considered if P, .05.
After the first set of statistical analyses, the design matrix
for neuroimaging data was created. VBM analyses were per-
formed by fitting a voxelwise general linear model as imple-
mented in SPM12. The design involved gender (F/M), age
(interacting with APOE ε4 status), p-tau, diagnostic category
(Ctrl/PreAD/MCI/AD), APOE ε4 status (carrier/noncarrier),
and the CSF glial biomarkers interacting with APOE ε4 sta-
tus. The interaction between age and APOE ε4 was consid-
ered after previous reports of carriers showing a steeper age-
related decline of cortical thickness not only in brain regions
associated with aging but also with Alzheimer’s disease and
Ab accumulation [46]. As data were modulated, total intra-
cranial volume was used as a global regressor. Therefore,
voxelwise gray-matter volumes were modeled as follows:
GM_Volw 11TIV1Sex1Age  APOE ε41p
 tau1Diag1APOE ε41CSF_biomark  APOE (1)
where CSF_biomark was substituted by CSF YKL-40 and
sTREM2, accordingly. For both CSF glial biomarkers, dif-
ferences between correlation slopes between carriers and
noncarriers were sought after with t-contrasts for each diag-
nostic group and for the whole sample. Another model was
essayed including CSF Ab as regressor that was finallyTable 2
Results (F-statistic; P-value) of the univariate analyses of variance (ANOVAs) to
status, demographic factors, and disease stage (model 1) or core CSF AD biomar
CSF YKL-40
Model 1 (diagnostic) Model 2 (biomarker)
Age F(1,103) 5 16.969; P , .001 F(1,104) 5 19.770; P , .0
Sex F(1,103) 5 0.452; P 5 .503 F(1,104) 5 0.379; P 5 .53
APOE ε4 F(1,103) 5 6.024; P 5 .016 F(1,104) 5 6.107; P 5 .01
Diag F(3,103) 5 3.679; P 5 .015 -
Ab - F(1,104) 5 3.292; P 5 .07
p-tau - F(1,104) 5 20.777; P , .0
Abbreviations: CSF, cerebrospinal fluid; AD, Alzheimer’s disease.
NOTE: Statistically significant factors (P , .05) in bold.discarded as this variable had no impact on the results.
The statistical significance threshold was set to P, .001 un-
corrected. Only clusters that survived an extent threshold of
k 5 100 voxels were considered.
3. Results
3.1. Demographics
Table 1 displays the demographic characteristics and CSF
biomarker concentrations for the different diagnostic groups
broken down by APOE ε4 status. The distribution between
carriers and noncarriers was generally balanced between
diagnostic groups, except for controls in which the number
of ε41 subjects (N 5 5) significantly (P , .05) differed
from that of ε42 (N5 44). Only four subjects in our sample
were APOE ε4 homozygotes (2 MCI and 2 AD) whichtest for associations between levels of glial CSF biomarkers and APOE ε4
kers (model 2)
CSF sTREM2
Model 1 (diagnostic) Model 2 (biomarker)
01 F(1,103) 5 4.285; P 5 .041 F(1,104) 5 4.329; P 5 .040
9 F(1,103) 5 0.626; P 5 .431 F(1,104) 5 0.413; P 5 .522
5 F(1,103) 5 2.664; P 5 .106 F(1,104) 5 2.070; P 5 .153
F(3,103) 5 1.450; P 5 .233 -
3 - F(1,104) 5 2.203; P 5 .141
01 - F(1,104) 5 20.735; P , .001
Table 3
Location of the clusters found in the maps from the correlation of the GM volume in ε42 w.r.t. ε41 associated with the CSF YKL-40 in the AD continuum
Group (contrast) Distribution Brain regions
MNI coordinates
Cluster size Z-scorex y z
AD continuum (ε42 . ε1) Cluster 1 Cerebellum Crus L 234 250 242 2473 4.50
Cerebellum L & R
Vermis
Cluster 2 Fusiform R 36 276 28 226 3.87
Occipital Inf R
Lingual R
Cluster 3 Temporal Inf R 56 266 218 511 3.81
Temporal Mid R
Cluster 4 Frontal Med Orb L 210 52 210 206 3.81
Rectus R
Frontal Med Orb R
Cluster 5 Angular R 42 264 36 309 3.60
Occipital Mid R
Abbreviations: GM, gray matter; CSF, cerebrospinal fluid; AD, Alzheimer’s disease.
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erozygotes. Levels of core Alzheimer’s disease CSF bio-
markers were slightly more altered in APOE ε4 carriers
versus noncarriers. Specifically, APOE ε4 carriers displayed
lower CSF Ab through the studied sample as well higher
concentrations of CSF p-tau and t-tau. In addition, carriers
also displayed slightly lower TIV-corrected hippocampal
volumes (Table 1). However, none of these differences
reached statistical significance for any biomarker or diag-
nostic group. CSF YKL-40 and TREM values were signifi-
cantly associated in the whole sample (P , .001;
R2 5 0.252). When broken down by diagnostic group,
CSF YKL-40 and sTREM were significantly associated in
Ctrl (P 5 .009; R2 5 0.371) and Pre-AD (P 5 .018;
R2 5 0.537) and showed a tendency to signification in
MCI (P, .109; R25 0.315) and AD (P, .056; R25 0.503).Fig. 2. Interaction in the volumetric correlates of CSF YKL-40 between APOE ε4
showing a statistically significant interaction. (Right) Scatterplot and linear fits of g
for APOE ε4 carriers (red) and noncarriers (black). Abbreviations: a.u., arbitrary3.2. Statistical associations of CSF YKL-40
All two-way interactions did not reach statistical signif-
icance and were removed from the two statistical models.
Therefore, model 1 (diagnostic model) included demo-
graphic factors (age and sex), APOE ε4 status, and diag-
nostic category, whereas in model 2 (biomarker model),
the diagnostic factor was substituted by core AD CSF bio-
markers as covariates. In both statistical models, CSF
YKL-40 levels were increased in APOE ε4 carriers
(P 5 .016 and P 5 .015 for models 1 and 2, respectively)
and positively associated with age (P , .001), but not sex
(see Table 2 for further details). In the diagnostic model,
diagnostic category significantly predicted CSF YKL-40
(P5 .015): Age-corrected CSF YKL-40 levels were signif-
icantly higher for MCI APOE ε4 carriers than in noncarrierscarriers and noncarriers throughout all diagnostic groups. (Left) Brain areas
ray-matter volume in the right inferior temporal cortex versus CSF YKL-40
units; CSF, cerebrospinal fluid; GM, gray matter.
Fig. 3. Gray-matter volume interactions between CSFYKL-40 concentrations and APOE4 genotype at each diagnostic group. Glass brains show areas in which
the regression slope was significantly higher (P, .001, uncorrected) in noncarriers (ε42) versus carriers (ε41). The control group was excluded from the anal-
ysis due to the small number of APOE4 carriers (N5 4). Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; GM, gray matter; MCI, mild cogni-
tive impairment.
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cance on Pre-AD subjects (P 5 .074; Fig. 1). In the
biomarker model, CSF YKL-40 was positively associated
with p-tau (P, .001) and showed a tendency to significance
to be inversely associated with CSF Ab.3.3. Statistical associations of CSF sTREM2
All two-way interactions did not reach statistical signifi-
cance and were removed from the models. CSF sTREM2
showed a significant direct association with age in both sta-
tistical models (P 5 .041 and P 5 .040 for models 1 and 2,
respectively) but not APOE ε4 genotype (P 5 .106 and
P 5 .153 for models 1 and 2, respectively) nor sex (see
Table 2 for additional details). In the diagnostic model, diag-
nostic category did not have a significant impact on CSF
sTREM2 levels (P 5 .233). In the biomarker model, CSF
sTREM2 concentrations were positively associated with
CSF p-tau (P , .001) but not with Ab (P 5 .141). Age-
corrected CSF sTREM2 levels were not significantly
different between APOE ε4 carriers and noncarriers for
any diagnostic group.3.4. Brain volumetric correlates of CSF YKL-40 by APOE
ε4 genotype in the AD continuum
In the correlation analysis in the whole sample, which
included p-tau and the diagnostic group as covariates,
APOE ε4 carriers showed an inverse (negative) association
between CSF YKL-40 and gray-matter volumes, whereas
this association was direct (positive) in noncarriers. The
regression slopes of carriers and noncarriers were signifi-
cantly different (P , .001) as determined by the interaction
analysis. Brain areas displaying such behavior included the
cerebellum, fusiform, angular, and temporal regions
(Table 3). Fig. 2 shows this pattern, which included areasthat were previously described to negatively correlate with
CSF YKL-40 in amyloid-positive cognitively normal con-
trols and patients with amnestic MCI [20]. Similar areas
showed an inverted u-shape association with CSF YKL-40
in early Alzheimer’s disease patients [37]. On the other
hand, the inverse contrast did not show any significant clus-
ter neither at the group nor whole sample levels. Fig. 3 shows
equivalent maps broken down by diagnostic category, except
for controls given the low number of APOE ε4 carriers in this
group (N 5 4). The pattern of APOE ε4 modulation of the
association between CSF YKL-40 and gray-matter volume
is remarkably consistent along the clinico-biological contin-
uum of AD.
3.5. Brain volumetric correlates of CSF sTREM2 by
APOE ε4 genotype in the AD continuum
No statistically significant results were found in any of
the analyses comparing this biomarker in accordance to
APOE ε4 status. In the VBM analysis, no voxels survived
the significance thresholds in any of the t-contrasts
comparing CSF sTREM2 regression slopes between carriers
and noncarriers.4. Discussion
In this work, we have explored how the APOE genotype
modulates CSF YKL-40 and sTREM2 concentrations and
their brain structural correlates across cognitively healthy
individuals free of (Ctrls) and with (Pre-AD) amyloid pa-
thology, patients of MCI due to AD, and AD patients. To
this regard, it is important to take disease stage into account
when considering CSF YKL-40 and sTREM2 as AD bio-
markers. Our main finding is that APOE ε4 has a significant
impact on CSF YKL-40 concentrations and its cerebral
structural correlates. APOE ε4 carriers present with
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Pre-AD stages (Fig. 1). In addition, we found that APOE ε4
status modulated the association between CSF YKL-40
levels and gray-matter volume in brain areas previously
described to be associated with this biomarker in preclini-
cal, prodromal, and early AD [20,37] (Fig. 2). In these areas
and throughout the full AD continuum, APOE ε4 carriers
showed an inverse association between gray-matter volume
and CSF YKL-40 levels, whereas noncarriers displayed a
positive one (Fig. 3). These two regression slopes were
significantly different as we specifically sought for their in-
teractions depending on the APOE ε4 genotype. Please note
that CSF p-tau levels have been taken into account in all of
the analyses here reported, and therefore, our findings
should be regarded to be independent of tau-related cere-
bral atrophy. In addition, in our analysis, we also took
into account the distinct impact of APOE ε4 status on
age-related decline of gray-matter volume in accordance
with previous reports [46].
On the other hand, we did not detect any significant dif-
ferences between APOE ε4 carriers and noncarriers with
respect CSF sTREM2, in agreement with [32,33]. The
TREM2 receptor has been described to recognize ApoE
not only as a free soluble protein but also as a constituent
of amyloid plaques. APOE ε4 shows a similar binding
affinity to the TREM2 receptor as compared to the other
APOE isoforms [15]. This fact might account for the similar
CSF sTREM2 levels here observed in APOE ε4 carriers and
noncarriers.
Our finding of increased CSF YKL-40 levels in APOE
ε4 carriers contrasts with previous literature [18–20],
including one article published with the same sample
here studied [21]. Unlike these, we here sought for differ-
ences between carriers and noncarriers after accounting
for demographic and diagnostic factors. By taking them
into account, we improved the statistical power to detect
differences associated to the APOE genotype. It could be
hypothesized that increased amyloid pathology in APOE
ε4 carriers could explain this difference. However,
although APOE ε4 carriers in our sample tended to present
with slightly more abnormal AD progression biomarkers
within each diagnostic group—including lower CSF
Ab—these differences did not reach statistical signifi-
cance. On the other hand, we had previously described
an inverted u-shape relationship between CSF YKL-40
and gray-matter volume in the same brain areas [37]: At
lower concentrations, CSF YKL-40 was positively associ-
ated with gray-matter volume but for levels over 400 ng/
mL, approximately, this association changed sign and
became negative. Therefore, APOE ε4 carriers showing
an increased astroglial activation in response to similar
levels of brain pathology could simultaneously explainboth the higher YKL-40 levels in CSF and the inverse as-
sociation with gray-matter volume observed in this group
as compared with the positive one in noncarriers. Howev-
er, the evidence presented in this cross-sectional article
does not allow us to confirm this hypothesis and further
longitudinal studies are needed.
The main limitations of our work are the reduced sample
size and the lack of longitudinal data to track the described
dynamic changes in CSF YKL-40 and sTREM2 concentra-
tions and their associated cerebral correlates. Therefore,
our findings require confirmation in larger longitudinal
studies. Another relevant limitation of analyzing a reduced
sample size is that our VBM results were not corrected for
multiple comparisons. In this regard, our results can be use-
ful for performing statistical power calculations to estimate
sample size requirements for future studies. In addition, it re-
mains to be determined whether elevations in glial CSF bio-
markers actually correspond with increased cerebral
astroglial and/or microglial activation. To this end, longitu-
dinal in vivo studies of astroglial and microglial activation
and its structural correlates along the AD continuum are
most needed.
In conclusion, we detected increased CSF YKL-40 in
APOE ε4 carriers with abnormal AD core CSF biomarkers.
APOE ε4 carriers showed significantly lower regression
slopes with gray-matter volume across the full continuum
of AD. These findings are indicative of an increased astro-
glial activation in APOE ε4 carriers at similar levels of alter-
ations in AD core biomarkers. On the other hand, we did not
detect any differences between carriers and noncarriers with
respect CSF levels of sTREM2 or its cerebral structural cor-
relates.
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1. Systematic review: Literature was reviewed using
traditional sources, and studies investigating the rela-
tionship between APOE ε4, cerebrospinal fluid
(CSF) glial markers YKL-40, and sTREM-2 with
regional brain volumes across the spectrum of
Alzheimer’s disease (AD) are cited throughout the
article.
2. Interpretation: We identify that APOE ε4 carriers
display greater CSF levels of YKL-40 but not of
sTREM2. In addition, carriers showed a distinct as-
sociation between CSF YKL-40 and regional brain
volumes compatible with a greater astrocytic
response. These results support for a role of APOE ε4
in the regulation of astroglial response in the AD
continuum.
3. Future directions: (1) To track the fate of the swollen
brain regions in longitudinal studies. (2) To ascertain
whether elevated CSF glial markers actually corre-
late with neuroinflammation along the AD contin-
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